Abstract:The coronavirus family has many pathogens that cause severe human diseases, including SARS, MERS and COVID-19.Starting from the SARS outbreak in 2003, our group has been dedicated to understanding coronavirus Replication-Transcription Complexes (RTCs).During the early part of the COVID-19 outbreak, we rapidly initiated a structural study of SARS-CoV-2 RTCs, aiming to dissect the key mechanisms for SARS-CoV-2 in human cells and provide structural information to discover potent antivirals.With great efforts from our laboratory and outside collaborations, we successfully determined the structure of the central RTC (C-RTC) composed by nsp12 (RNAdependent RNA polymerase, RdRp) with cofactors nsp7 and nsp8 1 , providing the first picture to visualize this key antiviral target.We also elucidated the mechanism of C-RTC catalysis and how remdesivir (RDV) inhibits the synthesis of RNA.This was achieved by determining the structure of C-RTC in complex with the template-product duplex RNA and the active form of RDV 2 .Subsequently, we presented the structure of the elongation RTC (E-RTC), showing how nsp13 (helicase) unwinds the highly-ordered structure in genome to yield the functional template for RNA synthesis in C-RTC 3 .After that, we discovered a key intermediate state of RTC leading towards mRNA capping [Cap(-1)'-RTC], demonstrating the nsp12 NiRAN is indeed the key enzyme to catalyze the second capping action and how it presents nsp9 as an "adaptor" for the further recruitment of capping enzymes into RTC 4 .In a following study, we assembled Cap(0)-RTC by Cap(-1)'-RTC and nsp10/nsp14, showing how the co-transcriptional capping and an in trans backtracking mechanism for proofreading concert in one RTC 5 .In our most recent work, we discovered a previously unknown protein modification -RNAylation on nsp9, and demonstrated nsp12 NiRAN utilizes the RNAylated nsp9 and GTP as substrates to synthesize the GpppA cap core, reasoning a novel RNA capping pathway 6 .We also showed that the nucleotide analogue inhibitors (NAIs) can be linked to nsp9 by NiRAN and thus block the occurrence of RNAylation and GpppA formation, furthering the understanding of the mechanism of action of NAIs.An 'induce-and-lock' mechanism is proposed to design new inhibitors against SARS-CoV-2 RNA capping.These works not only provides a basis to understand SARS-CoV-2 proliferates in the host cells through a structural biology lens, but also sheds new light for antiviral development against rapidly emerging SARS-CoV-2 variants.1

Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid

Antiviral Drug Design Based on Structural Insights into the N-terminal Domain and C-terminal Domain of the SARS-CoV-2 Nucleocapsid Protein

A Story of SARS-CoV-2 RNA Capping

Investigation of protein-protein interactions and hotspot region on the NSP7-NSP8 binding site in NSP12 of SARS-CoV-2

Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine

A Mechanism for SARS-CoV-2 RNA Capping and Its Inhibition by Nucleotide Analog Inhibitors.

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Structural Basis for Inhibition of the SARS-CoV-2 nsp16 by Substrate-Based Dual Site Inhibitors

Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach

A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13

The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex with its viral partner nsp3a

In Vivo Structural Characterization of the SARS-CoV-2 RNA Genome Identifies Host Proteins Vulnerable to Repurposed Drugs.

Inhibition of SARS-CoV-2 replication by a ssDNA aptamer targeting the nucleocapsid protein

Protein-protein interaction of RdRp with its co-factor NSP8 and NSP7 to decipher the interface hotspot residues for drug targeting: A comparison between SARS-CoV-2 and SARS-CoV

Structural insights into the activity regulation of full-length non-structural protein 1 from SARS-CoV-2

Assessing the inhibitory effects of some secondary amines, thioureas and 1,3-dimethyluracil conjugates of (-)-cytisine and thermopsine on the RNA-dependent RNA polymerase of SARS-CoV-1 and SARS-CoV-2

Structural basis of RNA cap modification by SARS-CoV-2

N terminus of SARS-CoV-2 nonstructural protein 3 interrupts RNA-driven phase separation of N protein by displacing RNA

Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals

Structure and Function of N-Terminal Zinc Finger Domain of SARS-CoV-2 NSP2

Crystal structure of SARS‐CoV‐2 nsp10–nsp16 in complex with small molecule inhibitors, SS148 and WZ16